Vivo Capital — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)Sushmita Chanda(Executive Vice President - Preclinical Development)Brian Dowd(Executive Vice President - Controller)Lucinda Quan(Executive Vice President - General Counsel)
Board seatJack Nielsen· per SEC Form D · $92.2M raise · filed Nov 2023
Co-investorsRoche Venture FundMPM BioVentures 2014
Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.
AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US
John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)
Board seatNathan DauJack Nielsen· per SEC Form D · $22M raise · filed Dec 2021
Co-investors3E Bioventures CapitalKeiretsu ForumLife Sciences Greenhouse InvestmentsToba Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.